Sumitomo Mitsui DS Asset Management Company Ltd Grows Stock Position in Johnson & Johnson $JNJ

Key Points

• Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Johnson & Johnson by 5.1%, owning 563,634 shares valued at approximately $86.1 million.
• Insider trading activity saw EVP Jennifer L. Taubert sell 56,471 shares at an average price of $177.81, reducing her position by over 24%.
• Recent research reports provided a mixed outlook on Johnson & Johnson, with multiple analysts adjusting their price targets, resulting in a consensus rating of "Moderate Buy" and an average target price of $177.87.

Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 563,634 shares of the company's stock after purchasing an additional 27,567 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Johnson & Johnson were worth $86,095,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in JNJ. Nuveen LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth $1,369,188,000. GAMMA Investing LLC raised its stake in shares of Johnson & Johnson by 24,450.4% during the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after buying an additional 7,185,977 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after buying an additional 2,825,626 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $349,206,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 1.7%

JNJ traded down $2.95 during midday trading on Thursday, hitting $174.25. The company's stock had a trading volume of 8,191,781 shares, compared to its average volume of 7,028,085. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market cap of $419.66 billion, a P/E ratio of 18.64, a PEG ratio of 2.26 and a beta of 0.40. The firm has a 50-day moving average price of $172.42 and a two-hundred day moving average price of $161.62. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson's payout ratio is presently 55.61%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on JNJ. Bank of America lifted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. UBS Group boosted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Finally, Citigroup boosted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $177.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.